Last updated
UCB: M&A Activity
UCB completed $2B acquisition of Candid Therapeutics, acquiring two clinical-stage T cell engagers for autoimmune disorders
Source: MedCity News
- What happened
- UCB completed $2B acquisition of Candid Therapeutics, acquiring two clinical-stage T cell engagers for autoimmune disorders
- Who
- UCB · Biotech & Pharma · Australia & New Zealand
- When
- 2026-05-04
- Source
- MedCity News
- So what
- Consolidation shifts the leadership question from growth to integration.
The leadership read
Consolidation shifts the leadership question from growth to integration. For UCB in Biotech & Pharma, the demand moves toward transformation and integration leaders who can merge teams, systems and cultures without losing momentum. Across Oceania, watch whether the integration is properly resourced; deals are won or lost the year after they close.
Market context: Against a Talent Market Index of 122.7 (Hot) (up 17.8 month-on-month), Oceania is at easing (-24.9pts) on signal share.
UCB: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 32 tracked companies; 0.1% of MitchelLake's EMEA signal flow; 5 tracked across 118 days.
MitchelLake in this thematic
Also at UCB →
More signals across Biotech & Pharma
M&A Activity · Oceania
Teva Pharmaceuticals →Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
Partnership · Oceania
NeuroScientific Biopharmaceuticals →NeuroScientific Biopharmaceuticals has engaged Southern Star Research to conduct a phase two clinical trial of its StemSmart Crohn's disease therapy in Australia and the US.
Partnership · Oceania
AusBiotech →AusBiotech announced a strategic partnership with Tenmile venture capital firm to strengthen ecosystem connections and help Australian health startups access both domestic and international capital. The partnership extends prior collaboration on the Early Stage Innovation Forum and creates additional opportunities for startups and scale-ups.
M&A Activity · Americas
Amgen →Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.
M&A Activity · Americas
BioMarin Pharmaceutical Inc. →BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.
M&A Activity · EMEA
Boehringer Ingelheim →Boehringer Ingelheim acquired Evax AG, a Swiss biotech company specializing in equine health, expanding its animal health portfolio.
Where this lands in our work
- Private Equity →
Ownership change resets the executive requirement — value-creation leadership follows the deal.
- Executive Search: Oceania →
Our Oceania practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record